MedTrace Logo

Patient Research Cohort: Rapidly Evolving Multiple Sclerosis

NCT01044576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-03-08

Study results available
· View outcomes & findings →

Summary

The primary goal of the research cohort is to facilitate patient access to clinical trials testing new therapeutic interventions, or access to second- line treatments.

Secondary objectives of the research cohort study are to obtain detailed clinical phenotyping and immunological analysis of blood samples, aiming to identify and validate biomarkers of disease activity and response to treatment and prognostic markers.

Conditions

  • Relapsing-remitting Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • Imperial College Healthcare NHS Trust

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • Queen Mary University of London

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Cambridge

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Paolo A Muraro, MD · Imperial College London

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044576 on ClinicalTrials.gov